JANSSEN GETS APPROVAL FOR ANTI-EPILEPTIC DRUG
By Adnews Staff
Janssen-Ortho Inc. of Toronto was recently granted approval by Health Canada to market its anti-epileptic drug Topamax. The product is proven to reduce the frequency of seizures in adults, particularly in patients whose condition is not controlled by other drugs. Advertising for Janssen Ortho is done by DDB Healthcare of Toronto. PR is done by OEB International of Toronto. In clinical trials, 5% of patients became completely seizure free after using Topamax, 21% had a 75% reduction in seizure frequency and 57% of patients with secondarily generalized tonic-clonic seizures reported at least a 50% drop in seizures. Topamax is also available in the U.S., the United Kingdom and South Africa. It is awaiting approval in over 20 countries.